PhaSER Biomedical receives $2.3m drug discovery grant from the Gates Foundation
Every year, tuberculosis, malaria and HIV cause over five million deaths worldwide
Read More
Tag: hiv
ACSR to use digitised pathology for HIV-associated malignancies
The software has reduced the time to provide pathology data from days to hours
Read More
New £20m NIHR project announced to combat HIV in England
In England, an estimated 4,500 people are living with undiagnosed HIV
Read More
Aelix and Gilead announce results of HIV infection candidate
The study evaluated the safety, efficacy and immunogenicity of AELIX’s HIV vaccine
Read More
Pharma poised but no recorded monkeypox deaths
Global surveillance systems show that recorded cases do not include any deaths
Read More
NICE approves first long-acting jab for HIV to replace daily pills
The announcement follows a positive decision from the SMC in October 2021
Read More
Oxford researchers launch HIV vaccine trial
Vaccine will be evaluated in 13 HIV-negative adults aged 18-65 years old
Read More
Gilead seeks US approval for long-acting HIV drug lenacapavir
Lenacapavir is designed to inhibit HIV-1 replication by interfering with a number of ‘essential’ steps in the viral lifecycle
Read More
Gilead’s HIV therapy Biktarvy demonstrates long-term sustained efficacy
Data from two Phase III studies demonstrated durable viral suppression in HIV-1 patients
Read More
ViiV’s Rukobia wins EU authorisation to treat multidrug-resistant HIV
Rukobia is a first-in-class HIV attachment inhibitor
Read More
US green light for long-acting HIV regimen Cabenuva
Cabenuva consists of ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine
Read More
ViiV Healthcare continues HIV care partnership with Chelsea and Westminster Hospital
Partnership aims to transform HIV patient care with digital services
Read More
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
- Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination
- HUTCHMED begins phase 3 stage of pancreatic cancer trial
- Zenas reports strong phase 3 results for obexelimab in IgG4-related disease
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
